-
Risk of head and traumatic brain injuries associated with antidepressant use ...
Background Antidepressant use has been associated with an increased risk of falling, but no studies have been conducted on whether antidepressant use is associated with an... -
Cognitive and imaging markers in non-demented subjects attending a memory cli...
Background The natural history and disease mechanisms of Alzheimer’s disease and related disorders (ADRD) are still poorly understood. Very few resources are available to... -
IgM response against amyloid-beta in aging: a potential peripheral protective...
Background The immune system plays a major role in the pathogenesis of age-related dementia, including Alzheimer’s disease (AD). An insight into age-associated changes in the... -
Retained capacity for perceptual learning of degraded speech in primary progr...
Background Processing of degraded speech is a promising model for understanding communication under challenging listening conditions, core auditory deficits and residual... -
Disclosure of amyloid positron emission tomography results to individuals wit...
Background Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia has become standard practice in secondary prevention trials and also... -
Associations of Bcl-2 rs956572 genotype groups in the structural covariance n...
Background Alzheimer’s disease (AD) is a complex neurodegenerative disease, and genetic differences may mediate neuronal degeneration. In humans, a single-nucleotide... -
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort ...
Background There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s disease (AD) in the predementia stages and to predict the rate of... -
Anemia is associated with incidence of dementia: a national health screening ...
Background The aim of this study was to investigate whether anemia is associated with dementia incidence in the elderly. Methods Using the Korean National Health Insurance... -
A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to mo...
Background Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist... -
Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU h...
Background Alzheimer’s disease (AD) is the most common type of dementia, affecting one in eight adults over 65 years of age. The majority of AD cases are sporadic, with unknown... -
Distinct white matter microstructural abnormalities and extracellular water i...
Background: Mixed vascular and neurodegenerative dementia, such as Alzheimer’s disease (AD) with concomitant cerebrovascular disease, has emerged as the leading cause of... -
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer...
Background Alzheimer’s disease is characterized by aggregated β-amyloid and tau proteins, but the clinical presentations and patterns of brain atrophy vary substantially. A part... -
study design and first results
Background We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the... -
Data-driven identification of endophenotypes of Alzheimer’s disease progressi...
Background Given the complex and progressive nature of Alzheimer’s disease (AD), a precision medicine approach for diagnosis and treatment requires the identification of patient... -
Adaptive crossover designs for assessment of symptomatic treatments targeting...
Background: There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration of the hormone oxytocin has been... -
Human fibroblast and stem cell resource from the Dominantly Inherited Alzheim...
Background Mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) cause autosomal dominant forms of Alzheimer disease (ADAD). More than 280...
